Cart
sales@molnova.com
TM5007
CAS No. 342595-05-5
TM5007( —— )
Catalog No. M24291 CAS No. 342595-05-5
TM5007 is a poent inhibitor of plasminogen activator inhibitor-1 (PAI-1; IC50 of 29 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 273 | In Stock |
|
| 10MG | 410 | In Stock |
|
| 25MG | 674 | In Stock |
|
| 50MG | 954 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTM5007
-
NoteResearch use only, not for human use.
-
Brief DescriptionTM5007 is a poent inhibitor of plasminogen activator inhibitor-1 (PAI-1; IC50 of 29 uM).
-
DescriptionTM5007 is a poent inhibitor of plasminogen activator inhibitor-1 (PAI-1; IC50 of 29 uM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPAI-1
-
RecptorPAI-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number342595-05-5
-
Formula Weight560.7
-
Molecular FormulaC24H20N2O6S4
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC1=CSC(=C1)C2=CSC(=C2C(=O)O)NC(=O)CCCCC(=O)NC3=C(C(=CS3)C4=CC=CS4)C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Izuhara Y , Takahashi S , Nangaku M , et al. Inhibition of Plasminogen Activator Inhibitor-1 Its Mechanism and Effectiveness on Coagulation and Fibrosis[J]. Arteriosclerosis Thrombosis and Vascular Biology, 2008, 28(4):672-677.
molnova catalog
related products
-
XR 5118
XR 5118 is a small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 3.5 uM.
-
UK-371804
UK-371804 is a potent and selective inhibitor of urokinase-type plasminogen activator (uPA) with Ki of 10 nM.
-
Aleplasinin
Aleplasinin is a selective and orally active inhibitor of Plasminogen activator inhibitor-1(PAI-1) and a key negative regulator of the fibrinolytic system. Aleplasinin can be used in Alzheimer's disease studies.
